Mustafa Solak, M.D. is a medical doctor who graduated from Hacettepe University School of Medicine and has completed residencies at Istanbul Sisli Etfal Teaching and Research Hospital and a fellowship at Hacettepe University Cancer Institute. He specializes in Breast Cancer, Testicular Cancer, Ovarian Cancer, Lung Cancer, Head-Neck Cancer, and Gastrointestinal Cancers. He has also worked at the University of Texas MD Anderson Cancer Center, Hitit University Corum Training Hospital, and Medical Park Hospital.
Read more
2011 – 2015, (Internal Medicine Specialist) Istanbul University Istanbul School of Education and Career
Medicine Department of Internal Medicine
2015 – 2016, (Internal Medicine) Specialist Istanbul Haydarpasa Numune Training and Research Hospital
2016 – 2019, (Medical Oncology) Istanbul University Istanbul School of Medicine Department of Medical Oncology
2019 – 2021, (Medical Oncology Specialist) - Istanbul Haydarpasa Numune Training and Research Hospital
2021 – 2024, (Associate Professor) Marmara University School of Medicine Department of Medical Oncology
Memberships in Scientific Organizations
ASCO
ESMO
TTOD
AVOD
Publications
In the field of oncology, he has published over 30 peer-reviewed articles at both international and national levels.
Awards Received
EAACI The European Academy of Allergy and Clinical Immunology 2019 Best Poster Award
"The top 3rd verbal presentation, IGICC (11th International Gastrointestinal Cancers Conference – IGICC2021)"
Speeches Delivered at National Congresses, Conferences, and Symposia:
Courses, Meetings, and Certificates
ESMO certified Medical Oncologist since 2019
Read more
Experience
2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL
2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer
2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital
2020 - 2021 Yüzüncü Yıl University Faculty of Medicine
2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.
2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department
2018 - 2021 Yüzüncü Yıl University Faculty of Medicine
2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital
2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant
2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist
2012 - 2015 Suleiman the Magnificent Training and Research Hospital,
2008 - 2012 Haseki Training and Research Hospital
2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.
Education
2018
İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji
2018
İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji
2012
İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları
2012
İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları
2007
Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi
Read more
Professional Experience
Gayrettepe Florence Nigthingale Hospital
Medical Oncology Department
Besiktas/Istanbul/Turkey (ongoing)
Education:
He became Professor (22/April /2016)
Medical Oncology
Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)
Istanbul University Oncology Institue,
Department of Medical Oncology
Medical Oncology Fellowship (December 2001-December2004)
Istanbul University, Istanbul Medical Faculty
Hemodialysis Traning (May1996-January1997)
Istanbul University ,bCerrahpasa Medical Faculty
Internal Medicine Residency (November 1991-November 1996)
Istanbul University ,bCerrahpasa Medical Faculty
Ege University Medical Faculty (1985-1991)
Professional Experience
February 1999-November 2001
Metropolitan Florence Nigthingale Hospital
American Cancer Center, Gayrettepe/İstanbul
April1997- October 1998
Bayraktar Dialysis Center
Güngören/ Istanbul
Membership
Turkish Medical Oncology Association
ENET(European Neuroendocrine Tumour Society)
ESMO
ASCO
Read moreEducation
Career
20 top ranked Chemotherapy for colon cancer doctors in the world are represented on this page. The list includes only verified specialists known for their experience and high success rates.
The ranking is composed according to the Bookimed patient reviews and considers the rating of hospitals where doctors practice.
Top 5 Chemotherapy for colon cancer doctors on Bookimed.com:
The specialist’s CV contains details about the doctor’s expertise and work experience, education, scientific research, and languages spoken. Compare information on several specialists, read carefully about their experience, success rates, and methods they apply. Make sure the chosen doctor has relevant experience in the treatment of a medical issue you are looking for. Read reviews of patients who had a consultation with the chosen specialist.
Famous Chemotherapy for colon cancer doctors have vast experience, continue education constantly, participate in professional associations and have positive feedback from patients treated.
The price for the consultation on Chemotherapy for colon cancer varies between experts and depends on certain factors, such as:
To schedule your visit, just submit a request on Bookimed.com. Our coordinator will contact you to discuss the time and details of the appointment, so everything will go smoothly.
We can help to find the right doctors for Chemotherapy for colon cancer if you have any difficulties with a choice. Bookimed services are free for patients ♥
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Read more
Bookimed, a leading global medical tourism platform, is committed to helping clients looking for Chemotherapy for colon cancer by offering expert assistance and trustworthy medical solutions for every situation. Smart automatic ranking system is used to compose transparent clinic listings, meticulously maintained by a data scientist using AI for accuracy. The platform guarantees authenticity by publishing reviews from real patients after their treatments. Bookimed offers comprehensive medical solutions, with updates from clinics to ensure trustworthiness. The content about Chemotherapy for colon cancer, crafted by experienced medical authors and reviewed by specialists, adheres to Bookimed"s Editorial Guidelines, reflecting the platform"s commitment to delivering high-quality and clear health information. For more details or inquiries, feel free to contact us at marketing@bookimed.com or learn more about us and our mission here.
Doctor Yesim Yildirim is an oncologist certified by the European Society of Medical Oncology (ESMO). Affiliated with numerous hospitals in the United States and Turkey, including the University of Maryland Medical Center, Johns Hopkins Hospital and Memorial Sisli Hospital. She has over 20 years of experience and has a special interest in preventive medicine, diabetes, and hypertension. Holds an MBA in Healthcare Management and shares her expertise with Bookimed from 2022.
The Medical Advisory Board expert is a verified credible medical professional with solid theoretical background and practical experience in the field. The expert provides support related to medical content accuracy for medical writers and performs educational workshops to Bookimed coordinators serving patient requests.
The medical content creation under the expert’s control follows rigorous and well-established procedure to be informative, trustworthy, and transparent and making Bookimed.com a credible source of evidence-based health information.